Nuclear Medicine or Radiopharmaceuticals Market Synopsis

Nuclear Medicine or Radiopharmaceuticals Market Size Was Valued at USD 6.13 Billion in 2022, and is Projected to Reach USD 11.0 Billion by 2030, Growing at a CAGR of 7.6% From 2023-2030.

Nuclear medicine is a specialized field within the medical domain that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat diseases. Radiopharmaceuticals are compounds consisting of a radioactive substance (radionuclide) combined with a pharmaceutical agent. These substances emit gamma rays that can be detected by specialized cameras or scanners, allowing physicians to visualize and assess the functioning of organs or tissues within the body.

• In diagnostic procedures, radiopharmaceuticals are administered to patients orally, intravenously, or through inhalation. These compounds accumulate in specific organs or tissues, highlighting areas of abnormality or disease, enabling doctors to diagnose conditions such as cancer, heart diseases, or neurological disorders. Moreover, nuclear medicine is also employed in therapeutic treatments, such as targeted radiation therapy for certain cancers. Radiopharmaceuticals used in therapy deliver radiation directly to the affected area, minimizing damage to surrounding healthy tissues.
• The field of nuclear medicine continues to evolve, offering precise and non-invasive methods to diagnose and treat various medical conditions. Advancements in radiopharmaceutical development and imaging technologies contribute to more accurate diagnoses and targeted treatments, enhancing patient care and outcomes.

Nuclear Medicine or Radiopharmaceuticals Market Trend Analysis

Increasing Incidence of Chronic Diseases

• Across the globe, diseases such as cancer, cardiovascular disorders, and neurological ailments are on the rise, necessitating advanced diagnostic and treatment methodologies. Radiopharmaceuticals play a critical role in detecting and monitoring these chronic conditions, contributing significantly to their diagnosis and subsequent management.
• As populations age and lifestyles evolve, chronic diseases have become more prevalent, driving the demand for accurate and timely diagnostic tools. Nuclear medicine techniques utilizing radiopharmaceuticals provide non-invasive, precise imaging methods that enable early detection and monitoring of these ailments. This early identification facilitates prompt intervention and appropriate treatment planning, improving patient outcomes and prognosis.
• Moreover, the versatile applications of radiopharmaceuticals in oncology, cardiology, and neurology further emphasize their significance in managing chronic diseases. The ability of these compounds to target specific tissues or organs aids in delivering tailored treatments, thereby reducing the side effects commonly associated with conventional therapies. As a result, the increasing incidence of chronic diseases acts as a catalyst, fostering the demand for nuclear medicine and radiopharmaceuticals in the healthcare landscape.

Personalized Medicine

• Personalized medicine represents a significant opportunity within the nuclear medicine and radiopharmaceuticals market. This approach tailors’ medical decisions and treatments to individual patient characteristics, such as genetic makeup, lifestyle, and specific disease markers. In nuclear medicine, the use of radiopharmaceuticals allows for a highly personalized approach in diagnosing and treating various conditions. By utilizing these compounds, clinicians can precisely target and monitor disease progression at a molecular level, thereby enabling customized therapeutic interventions.
• Advancements in imaging technologies and radiopharmaceutical research have facilitated the development of more specific and sensitive diagnostic tools. These innovations enable medical professionals to identify biomarkers and disease characteristics unique to each patient. This detailed understanding permits the creation of personalized treatment plans, optimizing therapy effectiveness while minimizing adverse effects.
• Moreover, nuclear medicine's capability to provide functional and molecular imaging enhances the ability to detect diseases earlier, well before symptoms manifest clinically. This early detection, combined with personalized treatment strategies utilizing radiopharmaceuticals, holds promise for improved patient outcomes, reduced treatment-related side effects, and better overall healthcare management. As research and technology continue to progress, the integration of personalized medicine principles into nuclear medicine practices is poised to revolutionize disease diagnosis, treatment, and patient care.

Nuclear Medicine or Radiopharmaceuticals Market Segment Analysis:

Nuclear Medicine or Radiopharmaceuticals Market Segmented on the basis of type, modality, application, and end-users.

By Product Type, Diagnostic segment is expected to dominate the market during the forecast period

• During the forecast period, the diagnostic segment is anticipated to maintain its dominance within the nuclear medicine and radiopharmaceuticals market. The diagnostic applications of radiopharmaceuticals play a pivotal role in disease identification, staging, and treatment monitoring. Technological advancements in imaging modalities such as PET and SPECT have significantly boosted the demand for radiopharmaceuticals in diagnostic procedures.
• With an increasing prevalence of chronic diseases such as cancer and cardiovascular disorders, the need for precise and early disease detection has grown substantially. Radiopharmaceutical-based imaging techniques offer non-invasive, highly sensitive means to visualize and assess abnormalities at a molecular level. Moreover, the versatility of radiopharmaceuticals allows for a wide range of diagnostic applications across various medical specialties, cementing their position as a cornerstone in the diagnostic armamentarium. As a result, the diagnostic segment is expected to maintain its market dominance owing to its critical role in accurate disease diagnosis and effective treatment planning.

By End User, Hospitals segment held the largest share of 52.1% in 2022

• The hospitals segment has consistently held the largest market share in the nuclear medicine and radiopharmaceuticals domain. Hospitals serve as primary centers for patient care, diagnosis, and treatment, making them pivotal in the utilization of radiopharmaceuticals for various medical procedures. These institutions possess advanced imaging equipment and facilities necessary for conducting nuclear medicine diagnostics and treatments, contributing significantly to the segment's dominance.
• Hospitals' widespread adoption of nuclear medicine techniques, such as PET and SPECT scans, underscores their reliance on radiopharmaceuticals for precise disease diagnosis and therapy planning. The comprehensive infrastructure and expertise available in hospitals make them ideal settings for conducting complex nuclear medicine procedures. Moreover, the increasing number of hospitals worldwide, coupled with their focus on offering advanced healthcare services, solidify their position as the leading segment in the nuclear medicine and radiopharmaceuticals market. As hospitals continue to invest in cutting-edge technologies and expand their medical capabilities, their prominence in utilizing radiopharmaceuticals for diagnostics and treatments is expected to persist.

Nuclear Medicine or Radiopharmaceuticals Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is anticipated to maintain its dominant position in the nuclear medicine and radiopharmaceuticals market throughout the forecast period. The region's leadership is attributed to several factors, including well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and extensive research and development activities in the field of nuclear medicine.
• The presence of prominent market players, along with substantial investments in healthcare, contributes to North America's market dominance. Additionally, favorable government initiatives, supportive regulatory frameworks, and increased awareness about the benefits of nuclear medicine further fuel the market growth in this region. Moreover, a growing prevalence of chronic diseases, coupled with a rising geriatric population, boosts the demand for precise diagnostic and therapeutic procedures, which are effectively met by nuclear medicine technologies. As North America continues to emphasize technological advancements and healthcare improvements, its position as the leader in the nuclear medicine and radiopharmaceuticals market is expected to persist in the foreseeable future.

Nuclear Medicine or Radiopharmaceuticals Market Top Key Players:

• Actinium Pharmaceuticals Inc. (U.S.)
• Alliance Medical (U.K.)
• Avid Bioservices Inc(U.S.)
• Bayer Healthcare Pharmaceuticals (Germany)
• Bracco Diagnostics Inc. (Italy)
• Cardinal Health Inc. (U.S.)
• Ge Healthcare (U.S.)
• Ion Beam Applications S.A (Belgium)
• Jubilant Pharma (India)
• Lantheus Medical Imaging Inc. (U.S.)
• Medi-Radiopharma Ltd (Hungary)
• Nordion Inc. (Canada)
• Novartis/Advanced Accelerator Applications (France)
• Positron Corporation (U.S.)
• Radiopharm Theranostics Ltd. (U.S.)
• Curium (France)
• Eli Lilly And Company (U.S.)
• Fujifilm Toyama Chemical Co., Ltd. (Japan)
• Nihon Medi-Physics. Co. Ltd. (Japan)
• Samyoung Unitech (South Korea)
• Duchembio, Inc. (South Korea) and Other Major Players

Key Industry Developments in the Nuclear Medicine or Radiopharmaceuticals Market:

• In March 2023, the International Atomic Energy Agency (IAEA) inked a pact with an 11-member consortium comprising Japanese universities and scientific institutions. This collaboration falls under the Rays of Hope initiative, aimed at fortifying the nuclear medicine workforce across Asia and the Pacific region.
• In January 2023, NorthStar Medical Radioisotopes, a notable American pharmaceutical company, embarked on a strategic alliance with Inhibrx, Inc. The primary aim of this collaboration is the co-development and production of innovative radiopharmaceuticals meticulously crafted to combat cancer. Radiopharmaceuticals assume a pivotal role within the domain of medical imaging, serving the dual purpose of diagnosing and treating cancer, making this partnership a significant step in advancing cancer care.
• In December 2022, Polarean Imaging Plc, a distinguished player in the medical imaging technology sector, achieved a momentous milestone by securing approval from the U.S. Food and Drug Administration (FDA) for Xenoview. This groundbreaking diagnostic radiopharmaceutical, intended for utilization alongside magnetic resonance imaging, is specifically tailored for evaluating lung ventilation in a broad spectrum of patients, encompassing both pediatric and adult populations.
• In March 2022, pharmaceutical giant Novartis announced a momentous achievement – FDA's approval of Pluvicto. This groundbreaking drug is slated for treating adults grappling with an advanced form of cancer known as prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY PRODUCT TYPE (2016-2030)
   1. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. DIAGNOSTIC
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. THERAPEUTIC
7. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY MODALITY (2016-2030)
   1. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. POSITRON EMISSION TOMOGRAPHY (PET)
   5. ALPHA EMITTERS
   6. BETA EMITTERS
   7. BRACHYTHERAPY
8. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY APPLICATION (2016-2030)
   1. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. ONCOLOGY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. CARDIOLOGY
   5. NEUROLOGY
9. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY END USER (2016-2030)
   1. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITALS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. SPECIALTY CLINICS
   5. DIAGNOSTIC CENTERS
10. COMPANY PROFILES AND COMPETITIVE ANALYSIS
    1. COMPETITIVE LANDSCAPE
       1. Competitive Positioning
       2. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS Market Share By Manufacturer (2022)
       3. Industry BCG Matrix
       4. Heat Map Analysis
       5. Mergers & Acquisitions
    2. ACTINIUM PHARMACEUTICALS INC. (U.S.)
       1. Company Overview
       2. Key Executives
       3. Company Snapshot
       4. Role of the Company in the Market
       5. Sustainability and Social Responsibility
       6. Operating Business Segments
       7. Product Portfolio
       8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
       9. Key Strategic Moves And Recent Developments
       10. SWOT Analysis
    3. ALLIANCE MEDICAL (U.K.)
    4. AVID BIOSERVICES INC (U.S.)
    5. BAYER HEALTHCARE PHARMACEUTICALS (GERMANY)
    6. BRACCO DIAGNOSTICS INC. (ITALY)
    7. CARDINAL HEALTH INC. (U.S.)
    8. GE HEALTHCARE (U.S.)
    9. ION BEAM APPLICATIONS S.A (BELGIUM)
    10. JUBILANT PHARMA (INDIA)
    11. LANTHEUS MEDICAL IMAGING INC. (U.S.)
    12. MEDI-RADIOPHARMA LTD (HUNGARY)
    13. NORDION INC. (CANADA)
    14. NOVARTIS/ADVANCED ACCELERATOR APPLICATIONS (FRANCE)
    15. POSITRON CORPORATION (U.S.)
    16. RADIOPHARM THERANOSTICS LTD. (U.S.)
    17. CURIUM (FRANCE)
    18. ELI LILLY AND COMPANY (U.S.)
    19. FUJIFILM TOYAMA CHEMICAL CO., LTD. (JAPAN)
    20. NIHON MEDI-PHYSICS. CO. LTD. (JAPAN)
    21. SAMYOUNG UNITECH (SOUTH KOREA)
    22. DUCHEMBIO, INC. (SOUTH KOREA)
11. GLOBAL NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By PRODUCT TYPE
       4. Historic And Forecasted Market Size By MODALITY
       5. Historic And Forecasted Market Size By APPLICATION
       6. Historic And Forecasted Market Size By END USER
       7. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
12. INVESTMENT ANALYSIS
13. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET COMPETITIVE RIVALRY
TABLE 005. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET THREAT OF NEW ENTRANTS
TABLE 006. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET THREAT OF SUBSTITUTES
TABLE 007. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY TYPE
TABLE 008. DIAGNOSTIC MARKET OVERVIEW (2016-2028)
TABLE 009. THERAPEUTIC MARKET OVERVIEW (2016-2028)
TABLE 010. RESEARCH MARKET OVERVIEW (2016-2028)
TABLE 011. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY MODALITY
TABLE 012. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOISOTOPES MARKET OVERVIEW (2016-2028)
TABLE 013. POSITRON EMISSION TOMOGRAPHY (PET) RADIOISOTOPES MARKET OVERVIEW (2016-2028)
TABLE 014. BETA EMITTERS MARKET OVERVIEW (2016-2028)
TABLE 015. ALPHA EMITTERS MARKET OVERVIEW (2016-2028)
TABLE 016. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 017. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY APPLICATION
TABLE 018. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 019. THYROID MARKET OVERVIEW (2016-2028)
TABLE 020. CARDIOLOGY MARKET OVERVIEW (2016-2028)
TABLE 021. NEUROLOGY MARKET OVERVIEW (2016-2028)
TABLE 022. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 023. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET BY END USER
TABLE 024. HOSPITALS & DIAGNOSTIC CENTERS MARKET OVERVIEW (2016-2028)
TABLE 025. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 026. NORTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY TYPE (2016-2028)
TABLE 027. NORTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY MODALITY (2016-2028)
TABLE 028. NORTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY APPLICATION (2016-2028)
TABLE 029. NORTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY END USER (2016-2028)
TABLE 030. N NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY COUNTRY (2016-2028)
TABLE 031. EUROPE NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY TYPE (2016-2028)
TABLE 032. EUROPE NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY MODALITY (2016-2028)
TABLE 033. EUROPE NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY APPLICATION (2016-2028)
TABLE 034. EUROPE NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY END USER (2016-2028)
TABLE 035. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY COUNTRY (2016-2028)
TABLE 036. ASIA PACIFIC NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY TYPE (2016-2028)
TABLE 037. ASIA PACIFIC NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY MODALITY (2016-2028)
TABLE 038. ASIA PACIFIC NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY APPLICATION (2016-2028)
TABLE 039. ASIA PACIFIC NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY END USER (2016-2028)
TABLE 040. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY COUNTRY (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY TYPE (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY MODALITY (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY APPLICATION (2016-2028)
TABLE 044. MIDDLE EAST & AFRICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY END USER (2016-2028)
TABLE 045. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY COUNTRY (2016-2028)
TABLE 046. SOUTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY TYPE (2016-2028)
TABLE 047. SOUTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY MODALITY (2016-2028)
TABLE 048. SOUTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY APPLICATION (2016-2028)
TABLE 049. SOUTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY END USER (2016-2028)
TABLE 050. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET, BY COUNTRY (2016-2028)
TABLE 051. ACTINIUM PHARMACEUTICALS INC.: SNAPSHOT
TABLE 052. ACTINIUM PHARMACEUTICALS INC.: BUSINESS PERFORMANCE
TABLE 053. ACTINIUM PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 054. ACTINIUM PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. ALLIANCE MEDICAL: SNAPSHOT
TABLE 055. ALLIANCE MEDICAL: BUSINESS PERFORMANCE
TABLE 056. ALLIANCE MEDICAL: PRODUCT PORTFOLIO
TABLE 057. ALLIANCE MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. AVID BIOSERVICES INC: SNAPSHOT
TABLE 058. AVID BIOSERVICES INC: BUSINESS PERFORMANCE
TABLE 059. AVID BIOSERVICES INC: PRODUCT PORTFOLIO
TABLE 060. AVID BIOSERVICES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. BAYER HEALTHCARE PHARMACEUTICALS: SNAPSHOT
TABLE 061. BAYER HEALTHCARE PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 062. BAYER HEALTHCARE PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 063. BAYER HEALTHCARE PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. BRACCO DIAGNOSTICS INC.: SNAPSHOT
TABLE 064. BRACCO DIAGNOSTICS INC.: BUSINESS PERFORMANCE
TABLE 065. BRACCO DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 066. BRACCO DIAGNOSTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. CARDINAL HEALTH INC.: SNAPSHOT
TABLE 067. CARDINAL HEALTH INC.: BUSINESS PERFORMANCE
TABLE 068. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
TABLE 069. CARDINAL HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. GE HEALTHCARE: SNAPSHOT
TABLE 070. GE HEALTHCARE: BUSINESS PERFORMANCE
TABLE 071. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 072. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. ION BEAM APPLICATIONS S.A: SNAPSHOT
TABLE 073. ION BEAM APPLICATIONS S.A: BUSINESS PERFORMANCE
TABLE 074. ION BEAM APPLICATIONS S.A: PRODUCT PORTFOLIO
TABLE 075. ION BEAM APPLICATIONS S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. JUBILANT PHARMA: SNAPSHOT
TABLE 076. JUBILANT PHARMA: BUSINESS PERFORMANCE
TABLE 077. JUBILANT PHARMA: PRODUCT PORTFOLIO
TABLE 078. JUBILANT PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. LANTHEUS MEDICAL IMAGING INC.: SNAPSHOT
TABLE 079. LANTHEUS MEDICAL IMAGING INC.: BUSINESS PERFORMANCE
TABLE 080. LANTHEUS MEDICAL IMAGING INC.: PRODUCT PORTFOLIO
TABLE 081. LANTHEUS MEDICAL IMAGING INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 081. MEDI-RADIOPHARMA LTD: SNAPSHOT
TABLE 082. MEDI-RADIOPHARMA LTD: BUSINESS PERFORMANCE
TABLE 083. MEDI-RADIOPHARMA LTD: PRODUCT PORTFOLIO
TABLE 084. MEDI-RADIOPHARMA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 084. NORDION INC.: SNAPSHOT
TABLE 085. NORDION INC.: BUSINESS PERFORMANCE
TABLE 086. NORDION INC.: PRODUCT PORTFOLIO
TABLE 087. NORDION INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 087. NOVARTIS/ADVANCED ACCELERATOR APPLICATIONS: SNAPSHOT
TABLE 088. NOVARTIS/ADVANCED ACCELERATOR APPLICATIONS: BUSINESS PERFORMANCE
TABLE 089. NOVARTIS/ADVANCED ACCELERATOR APPLICATIONS: PRODUCT PORTFOLIO
TABLE 090. NOVARTIS/ADVANCED ACCELERATOR APPLICATIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 090. POSITRON CORPORATION: SNAPSHOT
TABLE 091. POSITRON CORPORATION: BUSINESS PERFORMANCE
TABLE 092. POSITRON CORPORATION: PRODUCT PORTFOLIO
TABLE 093. POSITRON CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 093. RADIOPHARM THERANOSTICS LTD.: SNAPSHOT
TABLE 094. RADIOPHARM THERANOSTICS LTD.: BUSINESS PERFORMANCE
TABLE 095. RADIOPHARM THERANOSTICS LTD.: PRODUCT PORTFOLIO
TABLE 096. RADIOPHARM THERANOSTICS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 096. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 097. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 098. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 099. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY TYPE
FIGURE 012. DIAGNOSTIC MARKET OVERVIEW (2016-2028)
FIGURE 013. THERAPEUTIC MARKET OVERVIEW (2016-2028)
FIGURE 014. RESEARCH MARKET OVERVIEW (2016-2028)
FIGURE 015. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY MODALITY
FIGURE 016. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOISOTOPES MARKET OVERVIEW (2016-2028)
FIGURE 017. POSITRON EMISSION TOMOGRAPHY (PET) RADIOISOTOPES MARKET OVERVIEW (2016-2028)
FIGURE 018. BETA EMITTERS MARKET OVERVIEW (2016-2028)
FIGURE 019. ALPHA EMITTERS MARKET OVERVIEW (2016-2028)
FIGURE 020. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 021. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY APPLICATION
FIGURE 022. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 023. THYROID MARKET OVERVIEW (2016-2028)
FIGURE 024. CARDIOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 025. NEUROLOGY MARKET OVERVIEW (2016-2028)
FIGURE 026. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 027. NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY END USER
FIGURE 028. HOSPITALS & DIAGNOSTIC CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 029. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 030. NORTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. EUROPE NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. ASIA PACIFIC NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. MIDDLE EAST & AFRICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 034. SOUTH AMERICA NUCLEAR MEDICINE OR RADIOPHARMACEUTICALS MARKET OVERVIEW BY COUNTRY (2016-2028)